Welcome

VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) therapeutics for the treatment of cancer, respiratory, and autoimmune diseases.

News

• 01.12.2010

  VentiRx Pharmaceuticals Raises $25 Million in Series A Extension Financing - Funds used for clinical development of the first selective TLR8 agonists